Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants

André B P van Kuilenburg*, Marjolein C H Pleunis-van Empel, Rick B Brouwer, Angelique E J Sijben, Daan G Knapen, Thijs H Oude Munnink, Jelmer J van Zanden, Jenny Janssens-Puister, Doreen Dobritzsch, Rutger Meinsma, Judith Meijer-Jansen, Silvy J M van Dooren, Raymon Vijzelaar, Ana Pop, Gajja S Salomons, Jan Gerard Maring, Klary E Niezen-Koning

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A DPD deficiency should be considered in case of severe toxicity even in the absence of common risk variants in DPYD.

Original languageEnglish
Article numbere2300599
Number of pages7
JournalJCO Precision Oncology
Volume8
DOIs
Publication statusE-pub ahead of print - 6-May-2024

Keywords

  • Humans
  • Dihydropyrimidine Dehydrogenase Deficiency/genetics
  • Capecitabine/adverse effects
  • Dihydrouracil Dehydrogenase (NADP)/genetics
  • Antimetabolites, Antineoplastic/adverse effects
  • Male
  • Female
  • Fatal Outcome
  • Middle Aged

Fingerprint

Dive into the research topics of 'Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants'. Together they form a unique fingerprint.

Cite this